Comparative Pharmacology
Head-to-head clinical analysis: OPTIMARK versus OPTIMARK IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OPTIMARK versus OPTIMARK IN PLASTIC CONTAINER.
OPTIMARK vs OPTIMARK IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gadolinium-based MRI contrast agent that increases signal intensity by shortening T1 relaxation time in tissues where it accumulates.
Gadolinium-based paramagnetic contrast agent. The gadolinium ion (Gd3+) has seven unpaired electrons and a high magnetic moment, which enhances the relaxation rates of surrounding water protons in tissues, increasing signal intensity on T1-weighted magnetic resonance imaging (MRI) scans.
0.1 mmol/kg (0.2 mL/kg) intravenously as a single bolus injection; not to exceed 20 mL per dose.
0.2 mL/kg (0.1 mmol/kg) IV bolus; may repeat once within 30 minutes for total dose of 0.4 mL/kg (0.2 mmol/kg) if needed for contrast-enhanced MRI.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours in patients with normal renal function. In patients with severely impaired renal function (GFR <30 mL/min), half-life is significantly prolonged (up to 20 hours).
Terminal elimination half-life is approximately 2 hours in patients with normal renal function. In patients with severe renal impairment (GFR < 30 mL/min), half-life may be prolonged up to 30 hours.
Primarily renal excretion (glomerular filtration). >95% of the administered dose is eliminated unchanged in urine within 24 hours. Biliary/fecal elimination is negligible (<1%).
Primarily renal excretion via glomerular filtration; >90% of administered dose eliminated unchanged in urine within 24 hours. Less than 1% eliminated in feces.
Category C
Category C
MRI Contrast Agent
MRI Contrast Agent